Residual and Recurrent Gastrointestinal Stromal Tumors With KIT Mutations: Findings at First Follow-Up CT After Imatinib Treatment

被引：3
|
作者：
Choi, Dongil [1 ,2 ]
Yoo, Eun Young [1 ,2 ]
Kim, Kyoung-Mee [3 ]
Sohn, Tae Sung [4 ]
Lee, Won Jae [1 ,2 ]
Lee, Ji Young [1 ,2 ]
Chang, Ilsoo [1 ,2 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Dept Radiol, Kangnam Ku, Seoul 135710, South Korea
[2] Sungkyunkwan Univ, Sch Med, Ctr Imaging Sci, Kangnam Ku, Seoul 135710, South Korea
[3] Sungkyunkwan Univ, Sch Med, Dept Pathol, Samsung Med Ctr, Seoul, South Korea
[4] Sungkyunkwan Univ, Sch Med, Dept Surg, Samsung Med Ctr, Seoul, South Korea
来源：
AMERICAN JOURNAL OF ROENTGENOLOGY | 2009年 / 193卷 / 02期
关键词：
cystic change; follow-up CT; gastrointestinal stromal tumor; GIST; imatinib treatment; KIT mutation; POSITRON-EMISSION-TOMOGRAPHY; TYROSINE KINASE; POOR-PROGNOSIS; CYSTIC CHANGES; MESYLATE; INHIBITION; METASTASES; RESISTANCE; DELETIONS; BIOLOGY;
D O I：
10.2214/AJR.08.2106
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OBJECTIVE. The purpose of this study was to correlate findings on the first follow-up CT after treatment with imatinib in patients with residual or recurrent gastrointestinal stromal tumors (GISTs) with the different types of KIT mutation present at initial resection. CONCLUSION. Residual and recurrent GISTs with KIT mutation of exon 11 deletion more frequently showed both tumor shrinkage and cystic change on 2-month follow-up CT images after the start of imatinib treatment than did other mutation types.
引用
收藏
页码：W100 / W105
页数：6
相关论文
共 50 条
  • [31] Prospective Observational Study of Imatinib Therapy in Japanese Patients with Advanced Gastrointestinal Stromal Tumors: Long-term Follow-up and Second Malignancy
    Kanda, Tatsuo
    Ishikawa, Takashi
    Hirota, Seiichi
    Yajima, Kazuhito
    Kosugi, Shin-ichi
    Ohashi, Manabu
    Suzuki, Satoshi
    Mashima, Yasuoki
    Ajioka, Yoichi
    Hatakeyama, Katsuyoshi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (07) : 578 - 585
  • [32] Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib An Exploratory Analysis of a Randomized Clinical Trial
    Joensuu, Heikki
    Wardelmann, Eva
    Sihto, Harri
    Eriksson, Mikael
    Hall, Kirsten Sundby
    Reichardt, Annette
    Hartmann, Joerg T.
    Pink, Daniel
    Cameron, Silke
    Hohenberger, Peter
    Al-Batran, Salah-Eddin
    Schlemmer, Marcus
    Bauer, Sebastian
    Nilsson, Bengt
    Kallio, Raija
    Junnila, Jouni
    Vehtari, Aki
    Reichardt, Peter
    JAMA ONCOLOGY, 2017, 3 (05) : 602 - 609
  • [33] Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors
    Gao, Jing
    Tian, Ye
    Li, Jian
    Sun, Naiping
    Yuan, Jiajia
    Shen, Lin
    MEDICAL ONCOLOGY, 2013, 30 (02)
  • [34] Gastrointestinal stromal tumors: Recommendations on diagnosis, therapy and follow-up care in Austria
    Ploner, Ferdinand
    Zacherl, Johannes
    Wrba, Friedrich
    Laengle, Friedrich
    Bareck, Evelyne
    Eisterer, Wolfgang
    Kuehr, Thomas
    Schima, Wolfgang
    Haefner, Michael
    Brodowicz, Thomas
    WIENER KLINISCHE WOCHENSCHRIFT, 2009, 121 (23-24) : 780 - 790
  • [35] A Multicenter Long-Term Study of Imatinib Treatment for Japanese Patients With Unresectable or Recurrent Gastrointestinal Stromal Tumors
    Ogata, Kyoichi
    Mochiki, Erito
    Ojima, Hitoshi
    Haga, Norihiro
    Fukuchi, Minoru
    Aihara, Ryuusuke
    Ando, Hiroyuki
    Uchida, Nobuyuki
    Toyomasu, Yoshitaka
    Suzuki, Masaki
    Kimura, Akiharu
    Kogure, Norimichi
    Yokobori, Takehiko
    Ohno, Tetsuro
    Kuwano, Hiroyuki
    JOURNAL OF SURGICAL ONCOLOGY, 2014, 110 (08) : 942 - 946
  • [36] Gastrointestinal stromal tumors of the jejunum and ileum - A clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up
    Miettinen, M
    Makhlouf, H
    Sobin, LH
    Lasota, J
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2006, 30 (04) : 477 - 489
  • [37] Gastrointestinal Stromal Tumor: A Method for Optimizing the Timing of CT Scans in the Follow-up of Cancer Patients
    Joensuu, Heikki
    Reichardt, Peter
    Eriksson, Mikael
    Hall, Kirsten Sundby
    Vehtari, Aki
    RADIOLOGY, 2014, 271 (01) : 96 - 103
  • [38] Relationship between efficacy of sunitinib and KIT mutation of patients with advanced gastrointestinal stromal tumors after failure of imatinib A systematic review
    Xie, Fuming
    Xiao, Weidong
    Jiang, Yahui
    Xia, Xiao
    Wang, Yaxu
    MEDICINE, 2019, 98 (19)
  • [39] Type and Gene Location of KIT Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon
    Incorvaia, Lorena
    Fanale, Daniele
    Vincenzi, Bruno
    De Luca, Ida
    Bartolotta, Tommaso Vincenzo
    Cannella, Roberto
    Pantuso, Gianni
    Cabibi, Daniela
    Russo, Antonio
    Bazan, Viviana
    Badalamenti, Giuseppe
    CANCERS, 2021, 13 (05) : 1 - 15
  • [40] Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate
    Goh, B. K. P.
    Chow, P. K. H.
    Chuah, K. L.
    Yap, W. M.
    Wong, W. K.
    EJSO, 2006, 32 (09): : 961 - 963
12345